PD-1/PD-L1免疫抑制剂治疗卵巢癌的临床应用进展

doi:10.12280/gjfckx.20210173

摘要/Abstract

摘要：

在女性生殖系统肿瘤中,卵巢癌的致死率是最高的。目前治疗卵巢癌的方法主要有手术联合放、化疗以及靶向治疗,但是对于患者的生存率没有明显改善。免疫治疗是近年提出的治疗卵巢恶性肿瘤的新策略,旨在增强患者免疫系统识别和攻击肿瘤细胞的能力。目前已有多种免疫疗法被证实有一定的疗效,其中程序性死亡蛋白-1（programmed death-1,PD-1）/程序性死亡蛋白配体-1（programmed death ligand-1,PD-L1）检查点抑制剂已进入临床用来改善晚期卵巢癌、复发性卵巢癌、铂敏感或者铂耐药卵巢癌患者的预后。最常见的PD-1/PD-L1免疫抑制剂包括纳武单抗、派姆单抗、阿特珠单抗、阿维单抗和度伐利尤单抗等,就这些免疫抑制剂在卵巢癌中的临床治疗进展,尤其是最新的联合治疗进展进行了综述。

关键词: 卵巢肿瘤, 免疫疗法, 程序性细胞死亡受体1, 抗原,CD274, 药物疗法,联合

Abstract:

Ovarian neoplasm has the highest mortality among female reproductive system tumors. The methods of treating ovarian cancer involve surgery combined with radiotherapy, chemotherapy and targeted therapy, yet there is no significant improvement in the survival rate of patients. Immunotherapy is a new strategy for malignant ovarian tumors and aims to boost the capacity of the immune system to recognize and attack tumor cells. Some of them have been proven to show effects, among which programmed death-1 (PD-1)/programmed death ligand-1 (PD-L1) checkpoint inhibitors had been applied to improve the prognosis of advanced, recurrent platinum-sensitive or platinum-resistant ovarian cancer patients. PD-1/PD-L1 inhibitors include Nivolumab, Pembrolizumab, Atezolizumab, Avelumab, Durvalumab, etc. In this paper, we reviewed the progress of PD-1/PD-L1 inhibitors for ovarian cancer especially the combination therapy.

Key words: Ovarian neoplasms, Immunotherapy, Programmed cell death 1 receptor, Antigens,CD274, Drug therapy,combination

毛若南, 姜伟. PD-1/PD-L1免疫抑制剂治疗卵巢癌的临床应用进展[J]. 国际妇产科学杂志, 2021, 48(6): 605-609.

MAO Ruo-nan, JIANG Wei. Progress in the Clinical Application of PD-1/PD-L1 Inhibitor in the Treatment of Ovarian Neoplasms[J]. Journal of International Obstetrics and Gynecology, 2021, 48(6): 605-609.

参考文献 26

[1]	Nash Z, Menon U. Ovarian cancer screening: Current status and future directions[J]. Best Pract Res Clin Obstet Gynaecol, 2020,65:32-45. doi: 10.1016/j.bpobgyn.2020.02.010. doi: 10.1016/j.bpobgyn.2020.02.010
[2]	Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018,68(6):394-424. doi: 10.3322/caac.21492. doi: 10.3322/caac.21492
[3]	Sharma P, Hu-Lieskovan S, Wargo JA, et al. Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy[J]. Cell, 2017,168(4):707-723. doi: 10.1016/j.cell.2017.01.017. doi: 10.1016/j.cell.2017.01.017
[4]	Li J, Stanger BZ. How Tumor Cell Dedifferentiation Drives Immune Evasion and Resistance to Immunotherapy[J]. Cancer Res, 2020,80(19):4037-4041. doi: 10.1158/0008-5472.CAN-20-1420. doi: 10.1158/0008-5472.CAN-20-1420
[5]	Spranger S, Gajewski TF. Mechanisms of tumor cell-intrinsic immune evasion[J]. Annual Review Cancer Biology, 2018,2(1):213-228. doi: 10.1146/annurev-cancerbio-030617-050606. doi: 10.1146/annurev-cancerbio-030617-050606
[6]	Hartnett EG, Knight J, Radolec M, et al. Immunotherapy Advances for Epithelial Ovarian Cancer[J]. Cancers (Basel), 2020,12(12):3733. doi: 10.3390/cancers12123733. doi: 10.3390/cancers12123733
[7]	Duan M, Fang M, Wang C, et al. LncRNA EMX2OS Induces Proliferation, Invasion and Sphere Formation of Ovarian Cancer Cells via Regulating the miR-654-3p/AKT3/PD-L1 Axis[J]. Cancer Manag Res, 2020,12:2141-2154. doi: 10.2147/CMAR.S229013. doi: 10.2147/CMAR.S229013
[8]	Matsuo K, Spragg SE, Ciccone MA, et al. Nivolumab use for BRCA gene mutation carriers with recurrent epithelial ovarian cancer: A case series[J]. Gynecol Oncol Rep, 2018,25:98-101. doi: 10.1016/j.gore.2018.06.011. doi: 10.1016/j.gore.2018.06.011
[9]	Normann MC, Türzer M, Diep LM, et al. Early experiences with PD-1 inhibitor treatment of platinum resistant epithelial ovarian cancer[J]. J Gynecol Oncol, 2019,30(4):e56. doi: 10.3802/jgo.2019.30.e56. doi: 10.3802/jgo.2019.30.e56
[10]	Hamanishi J, Mandai M, Ikeda T, et al. Safety and Antitumor Activity of Anti-PD-1 Antibody, Nivolumab, in Patients With Platinum-Resistant Ovarian Cancer[J]. J Clin Oncol, 2015,33(34):4015-4022. doi: 10.1200/JCO.2015.62.3397. doi: 10.1200/JCO.2015.62.3397 pmid: 26351349
[11]	Zamarin D, Burger RA, Sill MW, et al. Randomized Phase II Trial of Nivolumab Versus Nivolumab and Ipilimumab for Recurrent or Persistent Ovarian Cancer: An NRG Oncology Study[J]. J Clin Oncol, 2020,38(16):1814-1823. doi: 10.1200/JCO.19.02059. doi: 10.1200/JCO.19.02059
[12]	Liu JF, Herold C, Gray KP, et al. Assessment of Combined Nivolumab and Bevacizumab in Relapsed Ovarian Cancer: A Phase 2 Clinical Trial[J]. JAMA Oncol, 2019,5(12):1731-1738. doi: 10.1001/jamaoncol.2019.3343. doi: 10.1001/jamaoncol.2019.3343
[13]	Matulonis UA, Shapira-Frommer R, Santin AD, et al. Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: results from the phase II KEYNOTE-100 study[J]. Ann Oncol, 2019,30(7):1080-1087. doi: 10.1093/annonc/mdz135. doi: S0923-7534(19)31241-4 pmid: 31987374
[14]	Varga A, Piha-Paul S, Ott PA, et al. Pembrolizumab in patients with programmed death ligand 1-positive advanced ovarian cancer: Analysis of KEYNOTE-028[J]. Gynecol Oncol, 2019,152(2):243-250. doi: 10.1016/j.ygyno.2018.11.017. doi: 10.1016/j.ygyno.2018.11.017
[15]	Zsiros E, Lynam S, Attwood KM, et al. Efficacy and Safety of Pembrolizumab in Combination With Bevacizumab and Oral Metronomic Cyclophosphamide in the Treatment of Recurrent Ovarian Cancer: A Phase 2 Nonrandomized Clinical Trial[J]. JAMA Oncol, 2021,7(1):78-85. doi: 10.1001/jamaoncol.2020.5945. doi: 10.1001/jamaoncol.2020.5945
[16]	Konstantinopoulos PA, Waggoner S, Vidal GA, et al. Single-Arm Phases 1 and 2 Trial of Niraparib in Combination With Pembrolizumab in Patients With Recurrent Platinum-Resistant Ovarian Carcinoma[J]. JAMA Oncol, 2019,5(8):1141-1149. doi: 10.1001/jamaoncol.2019.1048. doi: 10.1001/jamaoncol.2019.1048
[17]	Lee EK, Xiong N, Cheng SC, et al. Combined pembrolizumab and pegylated liposomal doxorubicin in platinum resistant ovarian cancer: A phase 2 clinical trial[J]. Gynecol Oncol, 2020,159(1):72-78. doi: 10.1016/j.ygyno.2020.07.028. doi: 10.1016/j.ygyno.2020.07.028
[18]	Liu JF, Gordon M, Veneris J, et al. Safety, clinical activity and biomarker assessments of atezolizumab from a Phase I study in advanced/recurrent ovarian and uterine cancers[J]. Gynecol Oncol, 2019,154(2):314-322. doi: 10.1016/j.ygyno.2019.05.021. doi: 10.1016/j.ygyno.2019.05.021
[19]	Moroney JW, Powderly J, Lieu CH, et al. Safety and Clinical Activity of Atezolizumab Plus Bevacizumab in Patients with Ovarian Cancer: A Phase Ib Study[J]. Clin Cancer Res, 2020,26(21):5631-5637. doi: 10.1158/1078-0432.CCR-20-0477. doi: 10.1158/1078-0432.CCR-20-0477
[20]	Zhang L, Chen Y, Li F, et al. Atezolizumab and Bevacizumab Attenuate Cisplatin Resistant Ovarian Cancer Cells Progression Synergistically via Suppressing Epithelial-Mesenchymal Transition[J]. Front Immunol, 2019,10:867. doi: 10.3389/fimmu.2019.00867. doi: 10.3389/fimmu.2019.00867 pmid: 31105696
[21]	Lampert EJ, Zimmer A, Padget M, et al. Combination of PARP Inhibitor Olaparib, and PD-L1 Inhibitor Durvalumab, in Recurrent Ovarian Cancer: a Proof-of-Concept Phase II Study[J]. Clin Cancer Res, 2020,26(16):4268-4279. doi: 10.1158/1078-0432.CCR-20-0056. doi: 10.1158/1078-0432.CCR-20-0056 pmid: 32398324
[22]	Lee JM, Cimino-Mathews A, Peer CJ, et al. Safety and Clinical Activity of the Programmed Death-Ligand 1 Inhibitor Durvalumab in Combination With Poly (ADP-Ribose) Polymerase Inhibitor Olaparib or Vascular Endothelial Growth Factor Receptor 1-3 Inhibitor Cediranib in Women′s Cancers: A Dose-Escalation, Phase I Study[J]. J Clin Oncol, 2017,35(19):2193-2202. doi: 10.1200/JCO.2016.72.1340. doi: 10.1200/JCO.2016.72.1340
[23]	Zimmer AS, Nichols E, Cimino-Mathews A, et al. A phase I study of the PD-L1 inhibitor, durvalumab, in combination with a PARP inhibitor, olaparib, and a VEGFR1-3 inhibitor, cediranib, in recurrent women′s cancers with biomarker analyses[J]. J Immunother Cancer, 2019,7(1):197. doi: 10.1186/s40425-019-0680-3. doi: 10.1186/s40425-019-0680-3
[24]	Zamarin D, Walderich S, Holland A, et al. Safety, immunogenicity, and clinical efficacy of durvalumab in combination with folate receptor alpha vaccine TPIV200 in patients with advanced ovarian cancer: a phase II trial[J]. J Immunother Cancer, 2020,8(1):e000829. doi: 10.1136/jitc-2020-000829. doi: 10.1136/jitc-2020-000829
[25]	Disis ML, Taylor MH, Kelly K, et al. Efficacy and Safety of Avelumab for Patients With Recurrent or Refractory Ovarian Cancer: Phase 1b Results From the JAVELIN Solid Tumor Trial[J]. JAMA Oncol, 2019,5(3):393-401. doi: 10.1001/jamaoncol.2018.6258. doi: 10.1001/jamaoncol.2018.6258 pmid: 30676622
[26]	Pujade-Lauraine E, Fujiwara K, Dychter SS, et al. Avelumab (anti-PD-L1) in platinum-resistant/refractory ovarian cancer: JAVELIN Ovarian 200 Phase III study design[J]. Future Oncol, 2018,14(21):2103-2113. doi: 10.2217/fon-2018-0070. doi: 10.2217/fon-2018-0070 pmid: 29584456